Celltrion has started to build a third plant and a global bioengineering research center on the site in Songdo New Town, Incheon, the company said on Nov. 18.
Celltrion will build a third plant of 60,000 liters of bio-medicine, and also build a "one-stop" large-scale research center to combine R&D and process development and clinical trials in order to establish a multi-species production and supply system in the future.
Its 3rd plant will have four stories with 4,700 square meters of land in the existing 2nd plant site, and the research center will be constructed with one basement floor and six stories above ground on 10,033 square meters of land near the 2nd plant.
Celltrion will invest a total of 500 billion won ($450 million), while the third plant will be completed in May 2023, and the research center will be completed in July 2022.
An official of Celltrion said, “With the construction of the third plant and research center, the company estimates that about 3,000 new jobs will be created, and the research center will have 2,000 specialized bio-development workers of them.”
“When the construction of the fourth plant is completed, celltrion’s production capacity will reach 450,000 liters in Korea alone,” he added.